Literature DB >> 18487277

Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia.

Joohyung Lee1, Wen-Mei Zhu, Davor Stanic, David I Finkelstein, Marjorie H Horne, Jasmine Henderson, Andrew J Lawrence, Louise O'Connor, Doris Tomas, John Drago, Malcolm K Horne.   

Abstract

Failed storage capacity, leading to pulsatile delivery of dopamine (DA) in the striatum, is used to explain the emergence of 'wearing off' and dyskinaesia in Parkinson's disease. In this study, we show that surviving DA neurons in 6-OHDA lesioned rats sprout to re-innervate the striatum, and maintain terminal density until approximately 60% of neurons are lost. We demonstrate that DA terminal density correlates with baseline striatal DA concentration ([DA]). Electrochemical and synaptosome studies in 6-OHDA lesioned rats and primates suggest that impaired striatal DA re-uptake and increased DA release from medial forebrain bundle fibres contribute to maintaining striatal DA levels. In lesioned rats where terminal density fell by 60% or more, L-DOPA administration increased striatal DA levels markedly. The striatal [DA] produced by L-DOPA directly correlated with the extent of dyskinaesia, suggesting that dyskinaesia was related to high striatal [DA]. While sprouting and decreased dopamine uptake transporter function would be expected to contribute to the marked increase in L-DOPA induced [DA], the increased [DA] was most marked when DAergic fibres were >60% denervated, suggesting that other release sites, such as serotonergic fibres might be contributing. In conclusion, the extent of dyskinaesia was directly proportional to the extent of DA terminal denervation and levels of extra-synaptic striatal DA. We propose that sprouting of DA terminals and decreased dopamine uptake transporter function prevent the appearance of Parkinsonian symptoms until about 60% loss of nigral neurons, but also contribute to dysregulated striatal DA release that is responsible for the emergence of dyskinaesia and 'wearing off'.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18487277     DOI: 10.1093/brain/awn085

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  32 in total

1.  Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease.

Authors:  K Elisabet Ohlin; Irene Sebastianutto; Chris E Adkins; Cornelia Lundblad; Paul R Lockman; M Angela Cenci
Journal:  Neuroimage       Date:  2012-03-03       Impact factor: 6.556

Review 2.  Presynaptic effects of levodopa and their possible role in dyskinesia.

Authors:  Eugene V Mosharov; Anders Borgkvist; David Sulzer
Journal:  Mov Disord       Date:  2014-12-01       Impact factor: 10.338

3.  Counteraction by nitric oxide synthase inhibitor of neurochemical alterations of dopaminergic system in 6-OHDA-lesioned rats under L-DOPA treatment.

Authors:  Elaine Del-Bel; Fernando Eduardo Padovan-Neto; Raphael Escorsim Szawka; Célia Aparecida da-Silva; Rita Raisman-Vozari; Janete Anselmo-Franci; Angélica Caroline Romano-Dutra; Francisco Silveira Guimaraes
Journal:  Neurotox Res       Date:  2013-06-27       Impact factor: 3.911

4.  In vivo measures of nigrostriatal neuronal response to unilateral MPTP treatment.

Authors:  LinLin Tian; Morvarid Karimi; Chris A Brown; Susan K Loftin; Joel S Perlmutter
Journal:  Brain Res       Date:  2014-05-15       Impact factor: 3.252

5.  ser31 Tyrosine hydroxylase phosphorylation parallels differences in dopamine recovery in nigrostriatal pathway following 6-OHDA lesion.

Authors:  Michael F Salvatore
Journal:  J Neurochem       Date:  2014-01-27       Impact factor: 5.372

6.  Effects of the Serotonin 5-HT1A Receptor Biased Agonists, F13714 and F15599, on Striatal Neurotransmitter Levels Following L-DOPA Administration in Hemi-Parkinsonian Rats.

Authors:  Adrian Newman-Tancredi; Mark A Varney; Andrew C McCreary
Journal:  Neurochem Res       Date:  2018-03-23       Impact factor: 3.996

7.  Sex-specific neuroprotection by inhibition of the Y-chromosome gene, SRY, in experimental Parkinson's disease.

Authors:  Joohyung Lee; Paulo Pinares-Garcia; Hannah Loke; Seungmin Ham; Eric Vilain; Vincent R Harley
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-01       Impact factor: 11.205

8.  Assessment of Wearing Off in Parkinson's disease using objective measurement.

Authors:  Parisa Farzanehfar; Holly Woodrow; Malcolm Horne
Journal:  J Neurol       Date:  2020-09-15       Impact factor: 4.849

9.  The pharmacological blockade of medial forebrain bundle induces an acute pathological synchronization of the cortico-subthalamic nucleus-globus pallidus pathway.

Authors:  Salvatore Galati; Paolo Stanzione; Vincenza D'Angelo; Ernesto Fedele; Francesco Marzetti; Giuseppe Sancesario; Teresa Procopio; Alessandro Stefani
Journal:  J Physiol       Date:  2009-07-21       Impact factor: 5.182

10.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.